TY - JOUR
T1 - TAB182 aggravates progression of esophageal squamous cell carcinoma by enhancing β-catenin nuclear translocation through FHL2 dependent manner
AU - Gao, Aidi
AU - Su, Zhenzi
AU - Shang, Zengfu
AU - He, Chao
AU - Miao, Dongliu
AU - Li, Xiaoqing
AU - Zou, Shitao
AU - Ding, Weiqun
AU - Zhou, Yue
AU - Sun, Ming
AU - Zhou, Jundong
N1 - Funding Information:
This work was supported by grants from the National Natural Science Foundation of China, Grant/Award Number: 81672975 and 81802341; Natural Science Foundation of Jiangsu Province (BK20220259); Suzhou Administration of Science & Technology, Grant/Award Number: SS2019013 and SYS2019091; Suzhou Key Medical Center, Grant/Award Number: SZZX201506; The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Grant/Award Number: GSKY202110211.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/10
Y1 - 2022/10
N2 - TAB182 (also named TNKS1BP1), a binding protein of tankyrase 1, has been found to participate in DNA repair. Our previous study has revealed the involvement of TAB182 in the radioresistance of esophageal squamous cell carcinoma (ESCC) cells. However, whether TAB182 contributes to the ESCC tumorigenesis and progression remains unclear. In this study, we found that highly expressed TAB182 is closely associated with a poor prognosis of patients with ESCC. TAB182 silencing reduced ESCC cell proliferation and invasion in vitro, tumorigenicity and metastasis in vivo. RNA-seq and IP-MS analysis revealed that TAB182 could affect the β-catenin signaling pathway via interacting with β-catenin. Furthermore, TAB182 prevented β-catenin to be phosphorylated by GSK3β and recruited four and a half of LIM-only protein 2 (FHL2), which thereby promoted β-catenin nucleus translocation to result in activation of the downstream targets transcription in ESCC cells. Our findings demonstrate that TAB182 enhances tumorigenesis of esophageal cancer by promoting the activation of the β-catenin signaling pathway, which provides new insights into the molecular mechanisms by which TAB182 accelerates progression of ESCC.
AB - TAB182 (also named TNKS1BP1), a binding protein of tankyrase 1, has been found to participate in DNA repair. Our previous study has revealed the involvement of TAB182 in the radioresistance of esophageal squamous cell carcinoma (ESCC) cells. However, whether TAB182 contributes to the ESCC tumorigenesis and progression remains unclear. In this study, we found that highly expressed TAB182 is closely associated with a poor prognosis of patients with ESCC. TAB182 silencing reduced ESCC cell proliferation and invasion in vitro, tumorigenicity and metastasis in vivo. RNA-seq and IP-MS analysis revealed that TAB182 could affect the β-catenin signaling pathway via interacting with β-catenin. Furthermore, TAB182 prevented β-catenin to be phosphorylated by GSK3β and recruited four and a half of LIM-only protein 2 (FHL2), which thereby promoted β-catenin nucleus translocation to result in activation of the downstream targets transcription in ESCC cells. Our findings demonstrate that TAB182 enhances tumorigenesis of esophageal cancer by promoting the activation of the β-catenin signaling pathway, which provides new insights into the molecular mechanisms by which TAB182 accelerates progression of ESCC.
UR - http://www.scopus.com/inward/record.url?scp=85140622330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140622330&partnerID=8YFLogxK
U2 - 10.1038/s41419-022-05334-2
DO - 10.1038/s41419-022-05334-2
M3 - Article
C2 - 36289198
AN - SCOPUS:85140622330
SN - 2041-4889
VL - 13
JO - Cell Death and Disease
JF - Cell Death and Disease
IS - 10
M1 - 900
ER -